Immunohistochemistry is a more sensitive marker for the detection of myeloperoxidase in acute myeloid leukemia compared with flow cytometry and cytochemistry.
Myeloperoxidase (MPO) is an unequivocal marker of myeloid differentiation which is routinely detected using cytochemistry (CC), flow cytometry (FC) and immunohistochemistry (IH). Several studies have compared the use of two of these methods, but to our knowledge none has compared all three techniques. We compared the performance of these three modalities in the detection of MPO in 158 cases of acute myeloid leukaemia (AML). Discrepancies were noted in a total of 28 cases. Of 110 cases in which all three modalities were performed, 23 cases showed discrepancies. CC was the least sensitive marker, being negative in 11 of 23 cases in the presence of positive IH and/or FC. IH was the most sensitive marker with only one case being negative in the presence of a positive result by FC and/or CC. The results highlight the necessity of employing more than one method in determining the presence of MPO and confirm the important role of IH in the diagnosis of AML particularly in cases where MPO is not detected by CC and FC.
Saravanan
L
L
Department of Diagnostic Haematology, Royal Melbourne Hospital, Victoria, Australia. Linda.Saravanan@petermac.org
Juneja
S
S
D014408:Biomarkers, Tumor / Q000032:analysis*; D005434:Flow Cytometry; D006651:Histocytochemistry; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis*; D009195:Peroxidase / Q000378:metabolism*
D014408:Biomarkers, Tumor; D009195:Peroxidase